New therapeutic approach identified for kidney disease associated with lupus
Investigators have identified a new disease mechanism and therapeutic approach for a type of advanced kidney disease that is a common cause of complications in patients with lupus. The study was led by investigators at Hospital for Special surgery and appears in Proceedings of the National Academy of Sciences.
"The standard treatment for lupus kidney disease is to block inflammation," said Lionel Ivashkiv, M.D., associate chief scientific officer at Hospital for Special Surgery in New York City. "This study suggests you might want to target the macrophages, a specific type of white blood cell involved in the disease."
For years, clinicians have known that kidney damage occurs in many patients with lupus, and they have known how the disease triggers the start of kidney disease. Little has been known, however, about one type of lupus kidney disease, proliferative crescentic disease that is associated with adverse outcomes and decreased survival. This type of kidney disease is characterized by abnormal proliferation (growth) of kidney cells that leads to irreversible damage to internal kidney structures that help filter waste and fluids from the blood. This advanced kidney disease leads to kidney failure and it is an important cause of the need for dialysis and transplantation in lupus.
Previous studies have suggested that type I interferons are implicated in promoting the autoimmunity associated with lupus. "We were interested in understanding whether these interferons might work directly on the kidney," Dr. Ivashkiv said. "There is a lot of evidence that the interferons work on the immune system and we wanted to know how interferons affect kidney disease."
To investigate, researchers used a mouse model of lupus. By increasing interferon production, they caused advanced kidney disease to occur in the mice rapidly. "The mice are a strain that will get nephritis over time, but we injected the mice at the very onset of the disease thus causing a very accelerated pattern, so that the mice have complete renal failure in two to four weeks," Dr. Ivashkiv said. They then examined the changes that occurred during the development of the advanced kidney disease by drawing blood samples from the mice, and analyzing their kidneys, and analyzing the macrophages to determine their type, among other experiments.
In the type of kidney disease they were investigating, it has long been known that epithelial cells proliferating out of control form a kind of crescent. These crescent cells compress the glomerulus, the basic filtration unit of the kidney, and prevent it from functioning.
In their experiments, the investigators found that the development of these crescents was associated with infiltrating kidney macrophages that produced growth factors, and the infiltration of these was spurred by interferon type I. They also found that the type of macrophages involved were not the most common type of inflammatory macrophages but so called "alternatively activated macrophages" that are involved in wound healing and induce the proliferation of cells. This is what causes the proliferation and crescentic lesions in the kidney disease.
"This study suggests a new drug target. If you could understand how to target the macrophages and inhibit them or the growth factors that they produce, this might be a different approach to therapy," Dr. Ivashkiv said. "This is an emerging area. Prior to this study, a role of macrophages had just been identified in lupus kidney disease, and this is the first study showing alternatively activated macrophages are involved in proliferative crescentic disease."
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Monsanto and Complix sign collaboration to bring new technologies to agriculture
Human Genome Science announces positive results of phase 2 clinical trial of Lymphostat-B in systemic lupus
Researchers decode new antibiotic - Combined attack minimizes resistance development
Japan's Ministry of Health, Labour and Welfare grants approval for Actelion's miglustat for the treatment of Niemann-Pick type C disease
How COVID-19 permanently damages the heart - Research team shows for the first time how the inflammation in COVID 19 alters the smallest vessels in the heart
Embryonic development and cancer cell growth - Embryonic factors for reprograming cancer cells
Chemotherapy or not? - Success in researching most effective methods for cancer therapy
Superdex™ 75 Increase, Superdex 200 Increase, Superose™ 6 Increase | Chromatography systems | Cytiva
